If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
HOME > ORGANIZATION
ORGANIZATION
- JPA, JSHP Announce Glossary of Standard Terminology for Drug Prescriptions
September 30, 2011
- No Correlation Between Drowsiness and Efficacy of 2nd-Generation Antihistamine Drugs: HIRS
September 30, 2011
- JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
- JPMA Asks for Continued R&D Tax Credit System
September 26, 2011
- Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
- FY2010 Deficit 2nd-Biggest Ever: Kenporen
September 26, 2011
- Over 95% of Patients Agree to Investigational Use of Removed Tissues: NCC Chief Director Kayama
September 22, 2011
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
- Keizai Doyukai’s Hasegawa Has Not Given Up on 5% Corporate Tax Cut
September 14, 2011
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
- JGA to Prepare Transparency GLs
September 6, 2011
- Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
- FPMAJ Proposes Setting NHI Prices for All Generics at or Above Minimum Statutory Prices
September 5, 2011
- JSGM Calls for Consideration of Generic Makers’ Cost Burden for Applications Based on Data in Public Domain
September 5, 2011
- Legal Prescription Rate Hits Record High 63.1% in FY2010: JPA
September 5, 2011
- 1st Meeting of Asia Cooperation Conference to Be Held Next March
September 5, 2011
ページ
Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…